Biocon has informed that the company and its subsidiaries Biocon Pharma \ and Biocon Pharma Inc. (‘Biocon’) has entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide).” The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.